Why
The Subcuject Wearable Bolus Injector (WBI) enables longer delivery time for larger, viscous doses compared to auto-injectors
Convenient delivery of biological drugs often requires an injection time over several minutes. The Subcuject WBI allows for self-administration of large doses over a pre-defined delivery period to avoid injection site leakage, local intolerability, injection pain etc. The drive mechanism is very robust towards variations in viscosity, back pressure etc.
Subcuject WBI enables reduced dosing frequency
The convenient self-administration of larger doses with the Subcuject WBI enables a change from delivery of many small doses to fewer larger doses.
Subcuject WBI enables cost saving in hospitals
Administration of pharmaceuticals via intra-veneous (IV) infusion in a hospital is costly. Patient self-administration of subcutaneous injections is expected to save from 30% to 70% of costs. In addition, the patient’s quality of life is improved with a self-administered wearable injector used in the home environment.
Close to 100 biologics (marketed or under development) are suited for delivery via Large Volume Wearable Injectors. These biologics are for treatment of chronic conditions, requiring frequent dosing, and are not currently available in suitable self-administration systems.
Roots Analysis